Accel Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Accel Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-300	Closed	-$2.04K	–	847
2023 Q1	$2.04K	Hold	300	–	–	﹤0.01%	1102
2022 Q4	$2.22K	Hold	300	–	–	﹤0.01%	896
2022 Q3	$3K	Hold	300	–	–	﹤0.01%	914
2022 Q2	$3K	Hold	300	–	–	﹤0.01%	876
2022 Q1	$4K	Hold	300	–	–	﹤0.01%	840
2021 Q4	$5K	Buy	+300	New	+$5.23K	﹤0.01%	823

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Accel Wealth Management's VNDA Position: Q2 2023 in Review

Accel Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2023, closing a stake of 300 shares — an estimated $2.04K sold.

Accel Wealth Management first reported a position in VNDA in Q4 2021 and held it in 6 quarters. The position peaked at $5K in Q4 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

Accel Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Accel Wealth Management sold 300 Vanda Pharmaceuticals shares in Q2 2023, an estimated $2.04K.
Accel Wealth Management first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Accel Wealth Management's Vanda Pharmaceuticals position peaked at $5K in Q4 2021.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.